Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: 5,17,37,5,101,... who wrote (510)	2/1/1998 11:56:00 PM
From: flickerful	Read Replies (1) \| Respond to of 756

<<The company also will focus on developing three types of drugs: treatments for cancer, drugs for respiratory troubles, and generic versions of proprietary drugs that are hard to formulate or have ingredients available only from a few suppliers. "The easier the drug is to make, the more likely you are going to have 14 competitors," Bethune said.>> smart. let's hope they stick to it. <<Eight other generic drugs are pending approval, and company officials expect to file 15 additional applications this year.>> zorifax...it's possible. <<Last year, Ivax received approval for seven generic and one made-from-scratch medicine.>> one made-from-scratch medicine....ok, this is the herald tribune? or is that the term...generally used? funny. n December, saying that its low stock price could spur an unsolicited takeover bid, Ivax adopted so-called poison pill measures. At that time, Ivax's founder and chairman Phillip Frost said no efforts, "hostile or otherwise," were under way to acquire the company. our frosty.